CVT-510 (CV Therapeutics).
CVT-510, the lead compound from a series of selective adenosine A1 receptor agonists, is being developed by CV Therapeutics for the potential treatment of supraventricular tachycardias and atrial arrhythmias [224364], [299365]. Phase II trialsfor atrial fibrillation commenced in December 1999 [349469], while a phase III trial for paroxysmal supraventricular tachycardia (PSVT) began in June 2001; this multicenter, randomized, double-blind, placebo-controlled trial, was to determine the safety and efficacy of CVT-510 in the conversion of PS VT to normal sinus rhythm [414190]. Analysts at Morgan Stanley predicted in December 2001, that the product would befiled with the FDA in 2004 and be launched onto the US market in 2005, with revenues of US $25 million, rising to US $83 million in 2006 [435233].